Blueteq is not just about cost, it’s an opportunity to optimise antiretroviral therapy

Sinead Peare
Guys and St Thomas’ NHS Foundation Trust, UK
Blueteq is not just about cost, it’s an opportunity to optimise antiretroviral therapy

Sinéad Peare – Clinical Pharmacist (Long term Conditions – HIV)
Guys and St Thomas’ NHS Foundation Trust

No Conflict of Interest
What is Blueteq, and why do we use it?
As of 1st Dec 2022, 822 people identified, 677 people reviewed.

165 people (76%) remain on Symtuza.

410 people (61%) remain on current treatment.

The most common reasons for remaining on treatment were patient preference, the need for single tablet regimen or adherence.

£42,000 per month saved in drug costs.

267 people (39%) switched treatment.

73 people (27%) switched to more expensive regimens. This was most commonly seen in people taking Eviplera (47 people - 44%).

103 people (39%) who switched treatments switched to an STR.

95 people switched off a boosted PI all together, most commonly from those originally taking Evotaz or Rezolsta.
Conclusions

Despite 27% of people switching to more expensive regimens, £42,000 per month has been saved.

Single tablet regimens and adherence along with people’s preference were the main reason for treatment choices.

61% of people remained on current regimens, but 76% of people taking Symtuza remained on Symtuza.

Acknowledgements: Stephanie Tyler & Dr Ranjababu Kulasegaram at GSTT